Molecular Templates (MTEM)
(Delayed Data from NSDQ)
$1.36 USD
+0.02 (1.49%)
Updated Sep 19, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Molecular Templates Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 61 | 143 | 94 | 125 |
Receivables | 0 | 0 | 0 | 0 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 5 | 7 | 7 |
Total Current Assets | 17 | 68 | 148 | 101 | 140 |
Net Property & Equipment | 7 | 15 | 19 | 22 | 18 |
Investments & Advances | 0 | 0 | 9 | 0 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 7 | 5 | 5 |
Total Assets | 35 | 98 | 192 | 140 | 174 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 9 | 10 | 13 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 48 | 36 | 23 | 20 |
Total Current Liabilities | 17 | 57 | 47 | 38 | 36 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 6 | 33 | 8 | 19 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 36 | 35 | 15 | 3 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 1 | 2 | 8 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 31 | 113 | 127 | 81 | 71 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 457 | 430 | 418 | 328 | 267 |
Retained Earnings | -453 | -445 | -352 | -269 | -164 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | -15 | 66 | 59 | 103 |
Total Liabilities & Shareholder's Equity | 35 | 98 | 192 | 140 | 174 |
Total Common Equity | 4 | -15 | 66 | 59 | 103 |
Shares Outstanding | 5.30 | 3.70 | 3.70 | 3.30 | 2.40 |
Book Value Per Share | 0.79 | -4.09 | 17.75 | 17.98 | 42.93 |
Fiscal Year End for Molecular Templates Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 7 | 12 | 16 | 5 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 4 | 5 | 7 | 7 |
Total Current Assets | 12 | 11 | 17 | 23 | 12 |
Net Property & Equipment | 5 | 6 | 7 | 9 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 3 | 3 |
Total Assets | 27 | 27 | 35 | 44 | 36 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 3 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 3 | 4 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 3 | 12 | 16 | 19 |
Total Current Liabilities | 8 | 9 | 17 | 22 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 5 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 21 | 31 | 37 | 44 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 468 | 458 | 457 | 456 | 436 |
Retained Earnings | -460 | -452 | -453 | -449 | -445 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 6 | 4 | 7 | -9 |
Total Liabilities & Shareholder's Equity | 27 | 27 | 35 | 44 | 36 |
Total Common Equity | 7 | 6 | 4 | 7 | -9 |
Shares Outstanding | 6.50 | 6.50 | 5.30 | 5.30 | 3.70 |
Book Value Per Share | 1.09 | 0.90 | 0.79 | 1.28 | -2.35 |